EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN THE UK

被引：0

作者：

Aubrey, P. ^{[1
]}

Waker, M. ^{[2
]}

Levysohn, A. ^{[3
]}

Bodin, M. ^{[3
]}

Keady, S. ^{[3
]}

机构：

[1] Biogen Idec Ltd, Maidenhead, Berks, England

[2] MTW Consultancy Ltd, London, England

[3] Biogen Int GmbH, Baar, Switzerland

来源：

VALUE IN HEALTH | 2019年 / 22卷

关键词：

D O I：

10.1016/j.jval.2019.04.103

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PBI20

引用

页码：S50 / S50

页数：1

共 35 条

[1] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN BELGIUM
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S47 - S48
[2] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN SPAIN
Barbado, G.
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S50 - S50
[3] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN FRANCE
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S47 - S47
[4] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING AN ADALIMUMAB BIOSIMILAR FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN GERMANY
Roehrer, W.
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S47 - S47
[5] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING ADALIMUMAB BIOSIMILARS FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN ITALY
Gargioli, M.
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S51 - S51
[6] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING ADALIMUMAB BIOSIMILARS FOR THE TREATMENT OF ALL LICENSED ADULT ADALIMUMAB INDICATIONS IN IRELAND
Aubrey, P.
Waker, M.
Levysohn, A.
Bodin, M.
Keady, S.
[J]. VALUE IN HEALTH, 2019, 22 : S48 - S48
[7] EVALUATION OF THE COST SAVING POTENTIAL OF INTRODUCING BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN THREE REGIONS IN ITALY
Psachoulia, E.
Negrini, C.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A534 - A534
[8] ASSESSING THE COST SAVING POTENTIAL OF INTRODUCING BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN FRANCE, ITALY AND SWEDEN
Psachoulia, E.
Bresson, A.
Holmqvist, K.
Negrini, C.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A533
[9] ESTIMATION OF THE BUDGET SAVING POTENTIAL DUE TO THE INTRODUCTION OF BENEPALI®, AN ETANERCEPT BIOSIMILAR, FOR THE TREATMENT OF ALL LICENSED ADULT ETANERCEPT INDICATIONS IN SPAIN
Psachoulia, E.
Casahorran, V
[J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A534
[10] ASSESSING THE POTENTIAL COST SAVING POTENTIAL OF IMPLEMENTING BENEPALI®, AN ETANERCEPT BIOSIMILAR, USING DISCOUNT AGREEMENTS FOR THE TREATMENT OF ALL LICENSED ETANERCEPT INDICATIONS FOR ADULTS IN SWEDEN
Psachoulia, E.
Holmqvist, K.
[J]. VALUE IN HEALTH, 2016, 19 (07) : A533 - A533

← 1 2 3 4 →